non-viral drug delivery system market 2022 – Industry Growth by 2035
Roots Analysis has announced the addition of “Non-Viral Drug Delivery Systems Market: Focus on Intracellular Technologies and Biologics (2nd Edition), 2022-2035” report to its list of offerings.
berry_cristan
Key Market Insights
§ Presently, over 90 non-viral drug delivery systems developers are engaged in the healthcare market, located across the globe
§ Currently, more than 95 non-viral drug delivery systems are offered by several players in the healthcare domain
§ The partnership activity for non-viral drug delivery systems in the healthcare domain has grown at a CAGR of over 40%, in the past three years, 2018-2021
§ The projected future opportunity for companies engaged in this field is expected to be well distributed across type of molecule, type of biologic delivered, type of technology, target therapeutic area, type of payment model and key geographical regions.
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Market Segmentations
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Need for Targeted Drug Delivery
3.3. Advanced Approaches for Delivery of Drug Payloads
3.3.1. Nanoparticle Delivery Systems
3.3.1.1. Liposomes
3.3.1.2. Nanoparticles / Microparticles
3.3.1.3. PEGylation
3.3.1.4. Cell Penetrating Peptides (CPPs)
3.3.2. Other Drug Delivery Technologies
3.4. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Intracellular Drug Delivery: List of Technologies
4.2.1. Analysis by Type of Molecule Delivered
4.2.2. Analysis by Type of Biologic Delivered
4.2.3. Analysis by Type of Interaction
4.2.4. Analysis by Therapeutic Portfolio
4.3. Intracellular Drug Delivery: List of Technology Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Company
4.3.4. Analysis by Location of Headquarters (By Region)
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Type of Technology
5.3. Analysis by Company Size and Type of Molecule Delivered
5.4. Analysis by Location of Headquarters (Region-wise) and Type of Service Provider
5.5. Analysis by Company Size and Location of Headquarters
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: Benchmarking of Portfolio Strength
6.5. Company Competitiveness Analysis: Benchmarking of Partnership Strength
6.5.1. Company Competitiveness Analysis: Very Small Companies
6.5.2. Company Competitiveness Analysis: Small Companies
6.5.3. Company Competitiveness Analysis: Mid-Sized Companies
6.5.4. Company Competitiveness Analysis: Large and Very Large Companies
7. COMPANY PROFILES
7.1. Arcturus Therapeutics
7.2. Bio-Path
7.3. CureVac
7.4. Entos Pharmaceuticals
7.5. eTheRNA immunotherapies
7.6. Matinas BioPharma
7.7. MDimune
7.8. PCI Biotech
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Intracellular Drug Delivery Technologies: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Application Year
8.3.4. Analysis by Cumulative Number of Granted Patents
8.3.5. Analysis by Cumulative Number of Patent Applications
8.3.6. Analysis by Issuing Authority
8.3.7. Analysis by Type of Player
8.3.8. Leading Players: Analysis by Number of Patents
8.3.9. Leading Inventors: Analysis by Number of Patents
8.3.10. Analysis by Top Sections
8.3.11. Intracellular Drug Delivery Technologies: Patent Benchmarking Analysis
8.4. Intracellular Drug Delivery Technologies: Patent Valuation Analysis
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Intracellular Drug Delivery Technologies: List of Partnerships and Collaborations
9.3.1. Cumulative Analysis of Partnerships by Year, 2015-2022
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership, 2015-2022
9.3.4. Analysis by Purpose of Partnership
9.3.5. Analysis by Type of Molecule Delivered
9.3.6. Analysis by Type of Biologic Delivered
9.3.7. Analysis by Target Therapeutic Area
9.3.8 Analysis by Year of Partnership and Type of Payment Model Employed, 2015-2022
9.3.9. Analysis by Year of Partnership and Type of Company, 2015-2022
9.3.10. Analysis by Purpose of Partnership and Type of Company
9.3.11. Most Active Players: Analysis by Number of Partnerships
9.3.12. Most Popular Technologies: Analysis by Number of Partnerships
9.3.13. Analysis by Region
9.3.14. Local and International Agreements
9.3.15. Intracontinental and Intercontinental Agreements
10. OPPORTUNITY ASSESSMENT FRAMEWORK: KALBACH INNOVATION MODEL, COMPETITVE ASSESSMENT FRAMEWORK AND BCG MATRIX
10.1. Chapter Overview
10.2. Kalbach Innovation Model
10.2.1. Key Assumptions and Methodology
10.2.2. Analysis by Trends in Research Activity
10.2.3. Analysis by Trends in Investment Activity
10.2.4. Analysis by Trends in Partnership Activity
10.2.5. Analysis by Number of Technologies
10.2.6. Analysis by Trends in Deal Amount
10.2.7. Analysis by Number of Google Hits
10.2.8. Qualitative and Quantitative Assessment based on Secondary and Primary Research
10.2.9. Kalbach Innovation Model: Output Analysis
10.3. Competitive Assessment Framework
10.3.1. Key Assumptions and Methodology
10.3.2. Competitive Assessment Framework: Output Analysis
10.4. BCG Matrix
10.4.1. Key Assumptions and Methodology
10.4.2. BCG Matrix: Output Analysis
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions
11.3. Forecast Methodology
11.4. Global Non-Viral Intracellular Drug Delivery Technologies Market, 2022-2035
11.5. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed, 2022 and 2035
11.5.1 Non-Viral Intracellular Drug Delivery Technologies Market for Milestone Payments, 2022-2035
11.5.2 Non-Viral Intracellular Drug Delivery Technologies Market for Upfront Payments, 2022-2035
11.6. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered, 2022 and 2035
11.6.1 Non-Viral Intracellular Drug Delivery Technologies Market for Biologics, 2022-2035
11.6.2 Non-Viral Intracellular Drug Delivery Technologies Market for Small Molecules, 2022-2035
11.7. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Biologic Delivered, 2022 and 2035
11.7.1 Non-Viral Intracellular Drug Delivery Technologies Market for RNA, 2022-2035
11.7.2 Non-Viral Intracellular Drug Delivery Technologies Market for DNA, 2022-2035
11.7.3 Non-Viral Intracellular Drug Delivery Technologies Market for Proteins / Peptides, 2022-2035
11.7.4 Non-Viral Intracellular Drug Delivery Technologies Market for Antibodies, 2022-2035
11.8. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Type of Technology, 2022 and 2035
11.8.1. Non-Viral Intracellular Drug Delivery Technologies Market for Nanoparticles, 2022-2035
11.8.2 Non-Viral Intracellular Drug Delivery Technologies Market for Extracellular Vesicles, 2022-2035
11.8.3 Non-Viral Intracellular Drug Delivery Technologies Market for Polymers, 2022-2035
11.8.4 Non-Viral Intracellular Drug Delivery Technologies Market for Oligonucleotides, 2022-2035
11.8.5 Non-Viral Intracellular Drug Delivery Technologies Market for Cell Penetrating Peptides, 2022-2035
11.9. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Target Therapeutic Areas, 2022 and 2035
11.9.1 Non-Viral Intracellular Drug Delivery Technologies Market for Infectious Diseases, 2022-2035
11.9.2 Non-Viral Intracellular Drug Delivery Technologies Market for Oncological Disorders, 2022-2035
11.9.3 Non-Viral Intracellular Drug Delivery Technologies Market for Genetic Disorders, 2022-2035
11.9.4 Non-Viral Intracellular Drug Delivery Technologies Market for Cardiovascular Disorders 2022-2035
11.9.5 Non-Viral Intracellular Drug Delivery Technologies Market for Hepatic Disorders, 2022-2035
11.9.6 Non-Viral Intracellular Drug Delivery Technologies Market for Neurological Disorders, 2022-2035
11.9.7 Non-Viral Intracellular Drug Delivery Technologies Market for Other Diseases, 2022-2035
11.10. Non-Viral Intracellular Drug Delivery Technologies Market: Analysis by Geography, 2022 and 2035
11.10.1. Non-Viral Intracellular Drug Delivery Technologies Market in North America, 2022-2035
11.10.2. Non-Viral Intracellular Drug Delivery Technologies Market in Europe, 2022-2035
11.10.3. Non-Viral Intracellular Drug Delivery Technologies Market in Asia, 2022-2035
11.10.4. Non-Viral Intracellular Drug Delivery Technologies Market in Rest of the World, 2022- 2035
11.10.5. Non-Viral Intracellular Drug Delivery Technologies Market in Middle East and North Africa, 2022-2035
11.10.6. Non-Viral Intracellular Drug Delivery Technologies Market in Latin America, 2022-2035
12. CONCLUDING REMARKS
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Biond Biologics
13.2.1. Interview Transcript: Tehila BenMoshe, Chief Executive Officer and Itay Friedman, Vice President Clinical Development
13.3. Carmine Therapeutics
13.3.1. Interview Transcript: Don Haut, Chief Executive Officer
13.4. Eyevensys
13.4.1. Interview Transcript: Thierry Bordet, Chief Scientific Officer
13.5. Generation Bio
13.5.1. Interview Transcript: Maren Killackey, Senior Director, Investor Relations and Communications
13.6. PCI Biotech
13.6.1. Interview Transcript: Anders Høgset, Research Director / Chief Scientific Officer
13.7. SRI International
13.7.1. Interview Transcript: Melissa Wagner, Strategic Business Executive, Biosciences Division
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html
You may also be interested in the following titles:
You may also like to learn what our experts are sharing in Roots educational series:
CAR-T Cell Therapies: Addressing Key Unmet Needs Across Various Oncological Indications
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
